読み込み中
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
前日終値
$4.95
−$0.04 · -0.80%
日中の時刻はETです。市場データは遅延する場合があります。
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
日中レンジ
現在 $4.95
52週レンジ
現在 $4.95
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
84
大幅な割安
センチメント
59
まちまち
リスク
58
やや高いリスク
モメンタム
60
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
日中レンジ
現在 $4.95
52週レンジ
現在 $4.95
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 794.58万 USD | 355.41万 USD | 600.22万 USD | — | — |
| 売上原価 | 2.74万 USD | 1186.57万 USD | 550.15万 USD | 441.25万 USD | — |
| 粗利益 | 791.84万 USD | −831.16万 USD | 50.07万 USD | −441.25万 USD | — |
| 研究開発 | 1673.45万 USD | 1189.07万 USD | 604.47万 USD | 493.75万 USD | 254.21万 USD |
| 販売・一般管理 | 1144.95万 USD | 888.58万 USD | 783.35万 USD | 484.71万 USD | 231.2万 USD |
| 営業費用 | 2818.4万 USD | 893.81万 USD | 840.4万 USD | 539.94万 USD | 487.03万 USD |
| 減価償却費と償却費 | 2.74万 USD | 2.74万 USD | 2.74万 USD | 2.74万 USD | 1.61万 USD |
| 営業利益 | −2026.56万 USD | −1724.97万 USD | −790.33万 USD | −981.19万 USD | −487.03万 USD |
| 純利益 | −2122.61万 USD | −1488.08万 USD | −798.78万 USD | −1224.48万 USD | −489.18万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI274.11万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF105.1万0.00%954億 USD0.05%$235+0.80%
Dimensional - US Small Cap ETFDFAS45.94万0.00%338.69億 USD0.31%$78.35+0.32%
iShares Micro-Cap ETFIWC31.16万0.02%13.17億 USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC19.22万0.00%75.58億 USD0.43%$57.813+0.20%
Avantis U.S. Small Cap Equity ETFAVSC5.6万—30.82億 USD0.25%$69.98+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4.14万0.00%61.81億 USD0.26%$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC2.73万0.00%885.96億 USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
